Illumina Launches Infinium® HTS-24 Arrays for Unparalleled Content and Sample Throughput Capacity

  Illumina Launches Infinium® HTS-24 Arrays for Unparalleled Content and
  Sample Throughput Capacity

   Illumina’s Most Popular Arrays Will Be Deployed on New Affordable Format

Business Wire

SAN DIEGO -- October 9, 2013

Illumina, Inc. (NASDAQ:ILMN) today launched an advanced high-throughput
screening (HTS) array format that significantly increases the number of
samples that can be processed on the Infinium® BeadChip family of genotyping
arrays. Illumina’s Infinium assay leverages proven chemistries on a new
24-sample HTS BeadChip that supports up to 750,000 markers per sample and
increases scanning capacity by up to three-fold.

“We're excited to introduce this new array format as it enables our customers
to perform larger, more powerful studies that enhance discovery,” said
Christian Henry, Senior Vice President and General Manager, Genomic Solutions
at Illumina. “The 24-sample HTS BeadChip strengthens Illumina’s leading
position in the array market and further demonstrates our ability to continue
innovation on our array platform, providing customers with high-quality,
high-throughput genotyping solutions. The new format allows us to offer
breakthrough pricing per sample which is important to enable
direct-to-consumer, biobanking, basic research, and agricultural
applications.”

Illumina’s HumanOmniExpress BeadChip will be the first standard array
available on the 24-sample HTS BeadChip, part of a portfolio of whole-genome
genotyping arrays with new affordable pricing. This powerful array contains
approximately 700,000 markers including the latest updates from the 1,000
Genomes Project strategically selected to capture the greatest amount of
common SNP variation and drive the discovery of novel associations with traits
and disease. It can also include up to 50,000 custom markers, making it ideal
for those interested in large genotyping studies such as core labs, genome
centers, and biobanks.

“We are very happy with the quality of data we obtained using the Illumina
Infinium technologies,” said Mark Kelleher, Director of Laboratory Operations
at 23andMe. “We are now very excited to deploy the higher-throughput BeadChips
to enhance our ability to process larger volumes of samples as we expand our
customer base.”

The first consortium-designed array on the 24-sample HTS BeadChip will
leverage the new format and affordable pricing to help researchers explore the
association between variants to five common cancers – breast, ovarian, colon,
lung, and prostate. The Infinium OncoArray-530K BeadChip (OncoArray), designed
in collaboration with leading experts from the OncoArray consortium and
enabled by the development of the 24-sample HTS BeadChip, delivers the core
content found on Illumina’s Infinium HumanCore array along with approximately
250,000 additional candidate variants identified by OncoArray consortium
members and room for 100,000 markers of semi-custom content. The consortium
members are planning a study of unprecedented size which will use the
OncoArray to analyze over 425,000 samples and detect subtle associations
within and between cancer types.

“The OncoArray is a major new tool for providing future insights into the
relationship between genetic variants and cancer predisposition,” said Doug
Easton, Professor of Genetic Epidemiology at Strangeways Research Laboratory,
University of Cambridge, and a leader of the OncoArray consortium. “It was
great working with Illumina to develop the OncoArray. The array contains the
custom content we need, in a high-throughput format that will make our
large-scale study feasible and should lead to a whole new wave of
discoveries.”

The HumanOmniExpress BeadChip is now shipping in the 24-sample HTS format. The
OncoArray, iSelect, HumanCoreExome, and HumanCore BeadChips in the 24-sample
HTS format are expected to begin shipping in Q1 2014. For more information,
please visit http://www.illumina.com/infiniumHTS.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release contains forward looking statements that involve risks and
uncertainties. Examples of forward-looking statements include, but are not
limited to, statements we make regarding the expected shipping date for the
OncoArray, iSelect, HumanCoreExome, and HumanCore BeadChips in the 24-sample
HTS format and the planned consortium study. Important factors that could
cause actual results to differ materially from those in any forward-looking
statements include challenges inherent in developing, manufacturing, and
launching new products and services and the other factors that are detailed in
our filings with the Securities and Exchange Commission, including our most
recent filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com